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Abstract
Introduction: We aimed to develop and validate a prognostic score for disability at discharge and functional outcome
at three months in patients with acute ischemic stroke based on clinical information available on admission.
Patients and methods: The Dutch Stroke Score (DSS) was developed in 1227 patients with ischemic stroke included
in the Paracetamol (Acetaminophen) In Stroke study. Predictors for Barthel Index (BI) at discharge (‘DSS-discharge’) and
modified Rankin Scale (mRS) at three months (‘DSS-3 months’) were identified in multivariable ordinal regression. The
models were internally validated with bootstrapping techniques. The DSS-3 months was externally validated in the
PRomoting ACute Thrombolysis in Ischemic StrokE study (1589 patients) and the Preventive Antibiotics in Stroke Study
(2107 patients). Model performance was assessed in terms of discrimination, expressed by the area under the receiver
operating characteristic curve (AUC), and calibration.
Results: At model development, the strongest predictors of Barthel Index at discharge were age per decade over 60
(odds ratio¼ 1.55, 95% confidence interval (CI) 1.41–1.68), National Institutes of Health Stroke Scale (odds ratio¼ 1.24
per point, 95% CI 1.22–1.26) and diabetes (odds ratio¼ 1.62, 95% CI 1.32–1.91). The internally validated AUC was 0.76
(95% CI 0.75–0.79). The DSS-3 months, additionally consisting of previous stroke and atrial fibrillation, performed
similarly at internal (AUC 0.75, 95% CI 0.74–0.77) and external validation (AUC 0.74 in PRomoting ACute
Thrombolysis in Ischemic StrokE (95% CI 0.72–0.76) and 0.69 in Preventive Antibiotics in Stroke Study (95% CI
0.69–0.72)). Observed outcome was slightly better than predicted.
Discussion: The DSS had satisfactory performance in predicting BI at discharge and mRS at three months in ischemic
stroke patients.
Conclusion: If further validated, the DSS may contribute to efficient stroke unit discharge planning alongside patients’
contextual factors and therapeutic needs.
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Introduction
In 2015, over 26,000 patients were admitted to hospi-
tals because of ischemic stroke in the Netherlands.1
Most of these patients need rehabilitation to achieve
better recovery in the first months after stroke and
reduce long-term disability. In the Netherlands,
around 8% of all stroke patients is referred to an inpa-
tient rehabilitation centre.2 Typically, these patients are
too disabled to be discharged home, but they are cog-
nitively and physically fit enough to participate in
intensive therapy sessions and have sufficient social
support to return home within two to four months.
Alternatively, patients may be referred to skilled nurs-
ing and geriatric rehabilitation facilities. These patients
are often elderly, suffer from comorbidities and have a
poorer functional prognosis. Still, the majority of
stroke patients (60%) is discharged home, mostly
with community rehabilitation.2 Discharge planning
may depend on multiple factors such as comorbidities
and contextual factors (e.g. the presence of a healthy
caregiver and premorbid level of functioning). The
importance of the contextual factors increases as the
functional prognosis of the stroke decreases.
Therefore, early prediction of functional outcome
may contribute to efficient discharge planning.
The most widely used functional outcome measure
in acute stroke is the modified Rankin Scale (mRS).
The mRS measures the degree of disability in daily
activities. It is scored on an ordinal scale ranging
from 0 (no symptoms) to 6 (death).3 Another frequent-
ly used outcome measure in rehabilitation is the Barthel
Index (BI), measuring performance in 10 basic activi-
ties of daily living (ADL).4 BI is associated with dura-
tion of hospital stay.5
Previous studies identified many prognostic factors
for outcome (measured by BI or mRS) after acute
stroke.6 Prognostic factors can be combined in a
model to identify patients at risk for poor outcome.7
Although several prognostic models exist to predict
outcome in stroke, very few are adequately validated
for use in daily clinical practice.8 We aimed to develop
and validate a prognostic score for disability (BI) at
discharge and functional outcome (mRS) at three
months after acute ischemic stroke based on clinical
information available on admission.
Methods
Derivation cohort
Data from the Paracetamol (Acetaminophen) In Stroke
(PAIS) study were used for model development.9 PAIS
was a multicentre, randomised placebo-controlled
phase III trial assessing the effect of high dose paracet-
amol on the functional outcome in patients with acute
stroke. In short, patients were eligible for inclusion if
they were diagnosed with acute ischemic stroke or
intracerebral hemorrhage, had a prestroke mRS< 2
and study treatment could be started within 12 h after
onset of symptoms. We used data of all patients with
ischemic stroke included in PAIS.
Outcome measures
We used the BI at discharge as the outcome measure
for short-term disability. The BI is an ordinal scale
used to measure performance in ADL. The scale
ranges from 0 to 20, with higher scores indicating a
greater likelihood of being able to carry out ADL inde-
pendently.4 In PAIS, the BI was measured at 14 days
after enrolment or at hospital discharge if this occurred
earlier (70% of the patients stayed for 3 days).9
However, choice of the optimal rehabilitation route
mostly depends on more than just discharge outcome.10
Therefore, we additionally evaluated functional out-
come at three months with the mRS. The mRS is an
ordinal scale used to measure the degree of disability in
daily activities and ranges from 0 (no symptoms) to 6,
with mRS 5 indicating severe disability and mRS 6
indicating death.3
Model development
To identify predictors of disability and functional out-
come, we selected variables that were clinically relevant
and/or previously reported to predict outcome after
stroke in the literature.6 These variables were sex,
age, National Institutes of Health Stroke Scale
(NIHSS) score, diabetes, previous stroke, atrial fibril-
lation and hypertension. All predictors were entered
into multivariable ordinal regression with backward
selection with p< 0.2 for inclusion, separately for BI
at discharge and mRS at three months. The final
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associations were presented as a set of odds ratios
(ORs) and 95% confidence intervals (CIs) to indicate
the individual predictor effects. ORs from an ordinal
logistic regression model can be interpreted as a
common OR for shifting over the full outcome range.11
The resulting models, the Dutch Stroke Score (DSS)
for BI at discharge (‘DSS-discharge’) and mRS at three
months (‘DSS-3 months’), were internally validated
using standard bootstrapping procedures to avoid an
optimistic estimate of the model performance, which
often occurs when model performance is only evaluated
directly in the derivation cohort (apparent validation).
In the bootstrap procedure, random samples are drawn
from the original sample, each with the same number
of patients as the original sample. In each of these
samples the modeling steps are repeated and the result-
ing models are subsequently evaluated on the original
sample. The mean model performance in all 500 boot-
strap models represents the expected performance of
the models in future, similar patients.12
Validation cohorts
For external validation, we used data from the
PRomoting ACute Thrombolysis in Ischemic StrokE
(PRACTISE) study and Preventive Antibiotics in
Stroke Study (PASS). PRACTISE was a cluster-
randomised trial designed to evaluate an implementa-
tion strategy to increase the proportion of patients
treated with intravenous thrombolysis.13 PRACTISE
registered adult patients with acute stroke admitted
within 24 h after onset of symptoms and had no age
restrictions. We used data from ischemic stroke
patients admitted within 4 h as in these patients
detailed clinical data were available.
PASS was a multicentre, randomised, open-label
trial designed to assess whether or not preventive anti-
microbial therapy with ceftriaxone improves functional
outcome in patients with acute stroke.14 PASS included
adult patients with clinical symptoms of a stroke (ische-
mic or hemorrhagic) admitted within 24 h after symp-
tom onset. We used data of all patients with ischemic
stroke included in PASS.
Model validation
The validity of the DSS-3 months was assessed in terms
of discrimination and calibration. The external valida-
tion cohorts did not have data on BI at discharge.
Discrimination refers to how well the model distin-
guishes between those who have good outcome (mRS
0–2) vs. those who have poor outcome (mRS 3–6) at
three months. Discrimination was assessed by calculat-
ing the ordinal area under the curve (AUC) of the
receiver operating characteristic (ROC) curve.15
The AUC ranges from 0.5 for non-informative
models to 1.0 for perfect models.12 Calibration indi-
cates the agreement between predicted and observed
probabilities. Calibration was assessed graphically in
a calibration graph, and expressed as the calibration
slope and an intercept. The calibration slope is ideally
equal to 1 and describes the effect of the predictors in
the validation cohort versus in the derivation cohort.
The intercept indicates whether predictions are system-
atically too high or too low, and should ideally be
zero.12
At external validation, the discriminative power of a
model may be influenced by differences in predictor
effects, but also by differences in distribution of patient
characteristics (case-mix) between the derivation and
validation cohort.16 In a more homogeneous popula-
tion, discrimination between patients with good vs.
poor outcome is more difficult than in a heterogeneous
population. To take this into account, we calculated
the case-mix-corrected AUC. The case-mix-corrected
AUC reflects the discriminative power of a model,
assuming that the regression coefficients are correct
for the validation population. It was calculated by sim-
ulating new outcome values for all patients in the val-
idation dataset, based on the predicted risks for each
patient.16
After external validation, we fitted the DSS-3
months on the combined data of all three trials to get
the best estimates for the regression coefficients.17 The
DSS-discharge and DSS-3 months were presented in a
score chart, as a score plot simplified to five BI and
mRS outcome classes (based on clinically relevant cut-
offs), and as formulas to calculate the predicted
outcomes.
All statistical analyses were performed using R soft-
ware, version 3.3.2 (R foundation for statistical com-
puting, Vienna, Austria). The calibration plots were
created with an updated version of the val.prob func-
tion (rms library in R). Missing values in the develop-
ment and validation cohorts were statistically imputed
using a multiple imputation method exploiting correla-
tions between predictor variables and between predic-
tor variables and the outcome variables (mice function
in R). Complete case analyses were done for compari-
son with the imputed analyses.
Results
Study population
For model development, we included 1227 patients
with ischemic stroke from the PAIS trial. Missing
data on hypertension (3.1%) were statistically imputed;
all other baseline variables and outcomes were com-
plete. For the external validation of the model
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predicting mRS at three months, we included, 1657
ischemic stroke patients from the PRACTISE study.
Sixty-eight patients with missing data on mRS at
three months were excluded, resulting in an external
validation sample of 1589 patients. Other missing
data (0.6%) were statistically imputed. Additionally,
we externally validated the model for functional out-
come at three months in, 2125 ischemic stroke patients
from the PASS study. Eighteen patients with missing
data on the mRS at three months were excluded, result-
ing in an external validation sample of 2107 patients.
Other missing data (0.4%) were statistically imputed.
In all three studies, most patients (55–58%) were
male and the mean age was around 70 years
(Table 1). The three populations are comparable con-
cerning baseline characteristics, except for time from
stroke onset to inclusion (PAIS and PRACTISE had
a smaller time window compared to PASS), previous
stroke (33% in PASS vs. 20% in the other trials) and
diabetes (20% in PASS vs. 15–17% in PAIS and
PRACTISE). The number of patients with poor out-
come (mRS 3–6) was lower in PASS compared to PAIS
and PRACTISE (online supplemental Figure 1(a)). In
PAIS, this is reflected in the substantial proportion of
patients with favorable outcome on the BI at discharge
(online supplemental Figure 1(b)).
Model development in PAIS
The relation between age as a continuous variable and
the log odds of disability (BI) in the development data
was non-linear and intensified when age was above 60
Figure 1. Calibration plots of the DSS-3 months in (a) PRACTISE and (b) PASS.
DSS: Dutch Stroke Score; PRACTISE: PRomoting ACute Thrombolysis in Ischemic StrokE; PASS: Preventive Antibiotics in Stroke
Study.
Table 1. Baseline characteristics of the included patients from the PAIS, PRACTISE and PASS studies.
PAIS (n¼ 1227) PRACTISE (n¼ 1589) PASS (n¼ 2107)
Male sex 675 (55%) 872 (55%) 1212 (58%)
Age in years (mean, sd) 70.1 (13.4) 70.6 (13.4) 71.9 (12.5)
Time from onset to CT in hours (median, IQR) 3.0 (1.8–5.9) 2.0 (1.4–3.0) NA
NIHSS (median, IQR) 6.0 (3.0–11.0) 5.0 (3.0–12.0) 5.0 (3.0–9.0)
Diabetes mellitus 181 (15%) 266 (17%) 423 (20%)
Previous ischemic stroke 245 (20%) 318 (20%) 698 (33%)
Atrial fibrillation 190 (16%) 290 (18%) 326 (16%)
Hypertension 601 (49%)a 811 (51%) 1154 (55%)
Current smoking 380 (31%) 374 (24%) 524 (25%)
NIHSS: National Institutes of Health Stroke Scale; IQR: interquartile range; NA: not available; PRACTISE: PRomoting ACute Thrombolysis in Ischemic
StrokE; PASS: Preventive Antibiotics in Stroke Study; PAIS: Paracetamol (Acetaminophen) In Stroke.
a38 Missings.
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years (online supplemental Figure 2). Because of this
non-linearity, we considered different age effects for
patients older vs. younger than 60 years.
Of the variables considered, age per decade above
60, NIHSS per point and diabetes were the strongest
predictors of BI at discharge, both in univariable (data
not shown) and multivariable analysis (Table 2) and
were included in the model for disability at discharge.
The internally validated ordinal AUC was 0.76 (95%CI
0.75–0.79). Age per decade above 60, NIHSS per point,
diabetes, previous stroke and atrial fibrillation were the
strongest predictors of mRS at three months, both in
univariable (data not shown) and multivariable analy-
sis (Table 2) and were included in the final model for
mRS at three months. The internally validated ordinal
AUC was 0.75 (95%CI 0.74–0.77).
External validation in PRACTISE and PASS
In PRACTISE, the DSS-3 months had an ordinal
AUC of 0.74 and an AUC for the cutoff mRS  3 of
Figure 2. DSS score charts simplified to five outcome classes of the (a) BI at discharge and (b) mRS at three months. Legend of (a):
Dark red¼0, Red¼1–9, Orange¼10–14, Yellow¼15–18, Green¼19–20 and legend of (b): Dark red¼6, Red¼4–5, Orange¼3,
Yellow¼2, Green¼0–1.
DSS: Dutch Stroke Score; BI: Barthel Index; mRS: modified Rankin Scale.
Table 2. Associations of predictors in multivariable ordinal regression with lower BI at discharge in PAIS and higher mRS at three
months in in PAIS, PRACTISE and PASS.
PAIS (n¼ 1227)
BI at discharge
PAIS (n¼ 1227)
mRS at three months
PRACTISE (n¼ 1589)
mRS at three months
PASS (n¼ 2107)
mRS at three months
Variable OR (95%CI) P value OR (95%CI) P value OR (95%CI) P value OR (95%CI) P value
Male sex 1.01 (0.79–1.23) 0.923 0.87 (0.71–1.07) 0.189 0.81 (0.67–0.97) 0.022 0.77 (0.61–0.93) 0.002
Age per decade
if over 60a,b
1.55 (1.41–1.68) <0.001 1.86 (1.64–2.12) <0.001 1.80 (1.61–2.01) <0.001 1.55 (1.41–1.70) <0.001
Age per decade
if under 60
1.07 (0.83–1.30) 0.589 0.93 (0.76–1.15) 0.514 0.89 (0.74–1.07) 0.211 0.70 (0.56–0.86) <0.001
NIHSS per pointa,b 1.24 (1.22–1.26) <0.001 1.19 (1.17–1.22) <0.001 1.19 (1.17–1.21) <0.001 1.21 (1.19–1.23) <0.001
Diabetesa 1.62 (1.32–1.91) 0.002 1.87 (1.40–2.51) <0.001 1.70 (1.34–2.17) <0.001 1.31 (1.11–1.51) 0.007
Previous strokeb 1.18 (0.91–1.45) 0.225 1.67 (1.29–2.16) <0.001 1.59 (1.27–1.99) <0.001 1.14 (0.98–1.31) 0.111
Atrial fibrillationb 1.09 (0.78–1.39) 0.592 1.41 (1.05–1.89) 0.022 1.24 (0.98–1.57) 0.076 1.14 (0.91–1.36) 0.264
Hypertension 1.06 (0.84–1.28) 0.594 1.02 (0.83–1.26) 0.844 1.08 (0.90–1.30) 0.384 0.91 (0.75–1.07) 0.246
BI: Barthel Index; mRS: modified Rankin Scale; OR: odds ratio; CI: confidence interval; NIHSS: National Institutes of Health Stroke Scale; PRACTISE:
PRomoting ACute Thrombolysis in Ischemic StrokE; PASS: Preventive Antibiotics in Stroke Study; PAIS: Paracetamol (Acetaminophen) In Stroke.
aParameter included in final model on BI at discharge.
bParameter included in final model on mRS at three months.
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0.81 (95%CI 0.81–0.84) (online Supplemental Table 1).
The model predicted 49.4% poor outcome (mRS  3);
whereas the observed probability of poor functional
outcome was 45.2%. The calibration slope was 1.022
and the intercept was 0.238, indicating that the
model’s predictions of poor outcome were systemati-
cally higher than the observed probability of poor out-
come (Figure 1(a)).
In PASS, the DSS-3 months had an ordinal AUC of
0.69 and an AUC for the cutoff mRS  3 of 0.81 (95%
CI 0.81–0.83) (online Supplemental Table 1).
The predicted probability of poor outcome was
48.6%, compared to an observed probability of poor
functional outcome of 38.5%. The calibration slope
was 1.058 and the intercept was 0.555, indicating
that the model’s predictions of poor outcome were sys-
tematically too high (Figure 1(b)). This overestimation
was higher than in PRACTISE.
The internal and external validation in the complete
cases (PAIS n¼ 1227, PRACTISE n¼ 1581, PASS
n¼ 2098) yielded similar results (not shown).
The lower discriminative ability of the DSS-3
months in the external validation cohorts was largely
explained by a less heterogeneous case-mix compared
to the development cohort. This is illustrated by small
differences between the development AUC and case-
mix-corrected AUCs (online Supplemental Table 1).
The lower discriminative ability in PASS compared
to PAIS and PRACTISE was due to both case-mix
and differences in predictor effects (relatively large
difference between AUC in external validation and
case-mix-corrected AUC in PASS).
The final DSS-3 months was developed on the com-
bined data of all three cohorts (n¼ 4923). The model
had an ordinal AUC of 0.73 and an AUC for the
cutoff mRS 3 of 0.81 (95%CI 0.81–0.83) (online
Supplemental Table 1).
The final models are presented as the DSS score chart
(Table 3, and simplified to five outcome classes in
Figure 2), with higher scores indicating worse outcome.
For example, a patient of 70 years with an NIHSS of 13
and a history of previous stroke and diabetes has a
DSS-discharge score of 8 and a predicted probability
of 17% for BI 19–20 at discharge and a DSS-3
months score of 13 and a predicted probability of
76% for mRS  3 at three months (online Appendix 1).
Discussion
We propose the DSS, consisting of two simple predic-
tion models for disability (BI) at discharge and func-
tional outcome (mRS) at three months after acute
ischemic stroke based on clinical information available
on admission. The DSS-discharge consists of three var-
iables: age per decade above 60 years, NIHSS per point
and diabetes. The DSS-3 months additionally includes
previous stroke and atrial fibrillation. Both models
showed reasonable performance in internal and exter-
nal validation.
Relation with previous literature
Previously, several models to estimate the probability
of unfavourable outcome after stroke have been devel-
oped, with a high variability in endpoints, time between
symptom onset and assessment of the variables, and
patient populations. Literature reviews have shown
that many of these prediction models have methodo-
logical shortcomings that limit their use for early dis-
charge planning. For instance, assessment of predictors
multiple days after stroke onset18,19 and the use of a
dichotomous outcome such as mortality.20–26 In addi-
tion, previously developed models were not validated,
and hence their use in clinical practice is limited.8,27
One tool has been developed specifically to predict
unfavorable discharge destination from the hospital
stroke unit. Functional disability, poor sitting balance,
depression, cognitive disability and old age were iden-
tified as predictors of poor discharge outcome.10
However, this model was only applicable for
decision-making at 7–10 days post stroke. Moreover,
this study had some methodological shortcomings,
including dichotomisation of predictors, a small
sample size and dichotomisation of the outcome.
Table 3. DSS score chart based on ordinal analysis of the BI and
mRS. A higher score indicates a worse outcome (lower predicted
BI and higher mRS).
Variable
Points for predicting
BI at discharge
Points for predicting
mRS score at 3 months
Age
<60 0 0
60–70 1 2
70–80 2 4
80–90 3 6
90þ 4 8
NIHSS
0 0 0
1–4 1 1
5–15 5 5
16–20 10 10
21–42 15 15
Diabetes 1 2
Previous stroke – 2
Atrial fibrillation – 1
Total 0–20 0–28
BI: Barthel Index; mRS: modified Rankin Scale; NIHSS: National Institutes
of Health Stroke Scale; DSS: Dutch Stroke Score.
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Implications of study findings
Prediction models in acute stroke are useful to inform
patients and relatives on prognosis and identify
patients at risk for poor outcome before treatment
decisions are made.7 On population level, prediction
models can be used for adjustment when comparing
quality of care for stroke patients across institutions.
Additionally, prediction models could be relevant in
design and analysis of randomised controlled trials,
e.g. for covariate adjustment.28,29 Further, prediction
of functional outcome may contribute to discharge
planning. If functional outcome is expected to be
poor, contextual factors, such as housing circumstan-
ces, financial problems and whether or not a patient is
living alone, become more important.
We developed the DSS to be used by stroke unit
nurses during the first day after admission. In clinical
practice, the NIHSS is mostly scored shortly after the
administration of alteplase. Therefore, we did not add
treatment with alteplase as a covariable to our analysis.
Recently, intra-arterial treatment administered within
six hours after stroke onset has been shown beneficial
in patients with a proximal intracranial arterial occlu-
sion.30 However, the majority (90%) of acutely admit-
ted ischemic stroke patients still receives intravenous
alteplase as only treatment. Therefore, the DSS is
potentially suitable for use in present neurovascular
practice. To facilitate discharge planning in
endovascular-treated patients, a next step could be to
update the models by including treatment (thromboly-
sis, thrombectomy or both) as a predictor. Moreover,
no imaging or laboratory tests are required for clini-
cians to be able to use the DSS, which allows bedside
use of the models early after admission. The DSS score
chart can be easily incorporated in clinical practice
since it consists of a few readily obtainable clinical var-
iables at admission. Stroke unit nurses will be able to
score all variables, including the NIHSS, provided that
they are well trained and certified.
The DSS-discharge still needs to be externally vali-
dated to give reliable estimates on model performance
and study generalisability.
At external validation, the discriminative ability of
the DSS-3 months was generally lower than in the
development sample. Discrimination was better in
PRACTISE compared to PASS, both for the ordinal
analysis of the mRS and for three different cutoffs of
the mRS (online Supplemental Table 1). These higher
AUCs were partly explained by differences in case-mix,
as reflected in the case-mix-corrected AUCs. In addi-
tion, the predictor effects were slightly stronger in
PRACTISE than in PASS. These differences in regres-
sion coefficients were most evident for diabetes and
previous stroke, and could be explained by
discrepancies in predictor definitions. For instance, in
PASS, previous stroke comprised both Transient
Ischemic Attack (TIA) and ischemic stroke, while in
PRACTISE only ischemic stroke was considered.
This implicates that the DSS-3 months is valid, but
the definitions of the predictors should be identical to
those in the development cohort.
The reasonable discriminative ability of the DSS-3
months was associated with an overall overestimation
of the probability of poor outcome. This overestima-
tion was higher in PASS compared to PRACTISE,
which might be due to the difference in outcome dis-
tribution between these cohorts (lower proportion of
patients with poor outcome in PASS). This difference
is most likely caused by the exclusion of patients with
imminent death and neurological deterioration in
PASS. The overestimation of the probability of poor
outcome implies that the DSS-3 months needs updating
(e.g. adjustment of the intercept (recalibration)) before
it is suitable for individualised predictions in clinical
practice.
Strengths and limitations
Strengths of this study are the internal and (partial)
external validation of the DSS, and the large size of
the development and two independent validation
cohorts. Even though many models have been devel-
oped for prediction of outcome after stroke, the large
sample size and the aim of contributing to efficient dis-
charge planning makes that our study has added value
compared to already existing evidence. Also, we pre-
dicted outcomes over the whole range from no symp-
toms to death. Furthermore, we used two well-known
and widely implemented outcome measures for func-
tional outcome in our models. The BI is a reliable and
valid scale to measure ADL.31 Since discharge destina-
tion (partially) depends on the patient’s ability to carry
out ADL, the BI is a suitable outcome for our model.
Additionally, we selected potential predictors based on
the literature and clinical knowledge. This is preferred
over selection based on the data as the latter may result
in overfitting (model perfect for the development data
but performing poor in new patients).12 The robustness
of our approach is represented in the reasonable per-
formance of the models in internal and external
validation.
Several limitations of our study need to be consid-
ered. We included only hospitalised patients with an
ischemic stroke in our analysis. Consequently, our
chart does not apply for patients with intracerebral
hemorrhage. Further, the development and validation
cohorts originated from randomised controlled trials
conducted in the Netherlands, potentially limiting the
generalisability of the chart. To evaluate the
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performance of the models beyond the Dutch setting,
external validation in observational data from settings
with a different healthcare system configuration is nec-
essary. However, the Dutch stroke population is repre-
sentative for stroke populations in developed countries.
Moreover, our external validation cohorts consist of
unselected, prospectively included patients, originating
from hospitals representative in size, geographic distri-
bution and frequency of stroke treatment procedures.
We were able to externally validate the DSS-3 months,
but not the DSS-discharge as no data on BI at dis-
charge were available. Also, discharge policy is variable
between and within different healthcare systems, which
makes it a difficult outcome for prediction purposes.
However, these differences in discharge timing resem-
ble the variation in clinical practice. Additionally, in
the field of rehabilitation, predicting functional out-
come in terms of the mRS has limitations. Important
aspects that can contribute to the level of disability and
the need for rehabilitation (e.g. pain, communication,
cognition) are not entirely covered by the mRS.32
However, the mRS is a widely used outcome measure
in stroke management.
The prognostic performance of the DSS after vali-
dation could be classified as satisfactory. This does not
disqualify the usefulness of the models for clinical prac-
tice, because in general, multivariable prediction
models are able to incorporate and accurately weigh
more factors than a human mind.33 Nevertheless, the
results should always be regarded as a mere recommen-
dation and should be placed in the context of the per-
sonal circumstances, needs and wishes of the patient.
Other factors that are worth considering when plan-
ning patients’ discharge are the presence of social sup-
port, cognitive disability, the therapeutic needs of the
patient and the expected future residence destination
(e.g. home or nursing facility).
Conclusion
The DSS has satisfactory performance in predicting BI
at discharge and mRS at three months in ischemic
stroke patients. If further validated, the DSS may con-
tribute to efficient stroke unit discharge planning
alongside patients’ contextual factors (e.g. social sup-
port, housing circumstances and cognitive disability)
and therapeutic needs.
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